Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized hUCMSC-Exos in Non-Acute Immune Checkpoint Inhibitor-Related Pneumonitis
NCT07599111Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
A Phase 2 trial of human umbilical cord mesenchymal stem cell-derived exosomes in Immune checkpoint inhibitor-related pneumonitis (CIP). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived exosomes
03
Conditions
Immune checkpoint inhibitor-related pneumonitis (CIP)
Beyond the preview
Go deeper on NCT07599111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599111.